Disappointing, but realistic update. As a long term holder, I'm happy to think that the buy-back can continue apace at the lower entry prices.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025